DE60331941D1 - Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert - Google Patents

Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert

Info

Publication number
DE60331941D1
DE60331941D1 DE60331941T DE60331941T DE60331941D1 DE 60331941 D1 DE60331941 D1 DE 60331941D1 DE 60331941 T DE60331941 T DE 60331941T DE 60331941 T DE60331941 T DE 60331941T DE 60331941 D1 DE60331941 D1 DE 60331941D1
Authority
DE
Germany
Prior art keywords
disease
fibrostenosis
crohn
fibrostenosing
nod2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331941T
Other languages
English (en)
Inventor
Maria T Abreu
Kent D Taylor
Jerome I Rotter
Huiying Yang
Kazuhito Sugimura
Stephan R Targan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of DE60331941D1 publication Critical patent/DE60331941D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60331941T 2002-08-30 2003-07-30 Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert Expired - Lifetime DE60331941D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40739102P 2002-08-30 2002-08-30
US10/356,736 US20040053263A1 (en) 2002-08-30 2003-01-30 Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
PCT/US2003/023926 WO2004020968A2 (en) 2002-08-30 2003-07-30 Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease

Publications (1)

Publication Number Publication Date
DE60331941D1 true DE60331941D1 (de) 2010-05-12

Family

ID=31981139

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331941T Expired - Lifetime DE60331941D1 (de) 2002-08-30 2003-07-30 Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert

Country Status (7)

Country Link
US (2) US20040053263A1 (de)
EP (1) EP1556405B1 (de)
JP (2) JP4606877B2 (de)
AT (1) ATE462710T1 (de)
AU (1) AU2003263834A1 (de)
DE (1) DE60331941D1 (de)
WO (1) WO2004020968A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828132B2 (en) * 2001-03-01 2004-12-07 Ultra Biotech Limited Biological fertilizer compositions comprising garbage
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7592150B2 (en) * 2003-12-03 2009-09-22 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies
US20060205022A1 (en) * 2003-12-03 2006-09-14 Nir Dotan Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease
EP1692519B1 (de) * 2003-12-03 2010-06-02 Glycominds Ltd. Diagnostikverfahren mittels messungen der antiglykan-antikörper-spiegeln
US7803535B2 (en) * 2004-03-27 2010-09-28 Hanns-Georg Klein Polymorphisms in the NOD2/CARD15 gene
US20080260753A1 (en) * 2004-04-09 2008-10-23 The Regents Of The University Of California Mouse Models of Crohn's Disease and a Method to Develop Specific Therapeutics
EP1819827B1 (de) * 2004-12-08 2010-08-11 Cedars-Sinai Medical Center Verfahren zur diagnose von morbus crohn
US10544459B2 (en) * 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
EP2049691A4 (de) * 2006-07-26 2010-06-16 Genizon Biosciences Inc Suszeptibilitätsgen für morbus crohn
CA2671267A1 (en) * 2006-11-30 2008-06-05 Navigenics Inc. Genetic analysis systems and methods
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
EP2220507B1 (de) * 2007-11-30 2012-09-12 Glycominds Ltd. Zusammensetzung und verfahren zur vorhersage eines komplizierten krankheitsverlaufs und von operationen bei morbus crohn
WO2009143278A2 (en) * 2008-05-20 2009-11-26 Cedars-Sinai Medical Center Methods of diagnosing and characterizing cannabinoid signaling in crohn's disease
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2010120814A1 (en) 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
WO2011088306A1 (en) * 2010-01-15 2011-07-21 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose crohn's disease
SG189391A1 (en) 2010-10-18 2013-05-31 Nestec Sa Methods for determining anti-drug antibody isotypes
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
JP2014515599A (ja) * 2011-03-25 2014-07-03 セダーズ−シナイ メディカル センター 炎症性腸疾患における腸の肉芽腫および低骨密度を診断および処置する方法
RU2013154566A (ru) 2011-05-10 2015-06-20 Нестек С.А. Способы анализа профиля активности болезни с целью проведения индивидуального лечения
CA2852954A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
CN115261411A (zh) 2013-04-04 2022-11-01 哈佛学院校长同事会 利用CRISPR/Cas系统的基因组编辑的治疗性用途
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
IL254734B2 (en) 2015-03-27 2023-09-01 Harvard College Modified t cells and methods for their preparation and use
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
US11913015B2 (en) 2017-04-17 2024-02-27 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
WO2020139748A1 (en) * 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157053B2 (ja) * 1992-09-16 2001-04-16 ティーディーケイ株式会社 Ｄｎａ作用物質の結合様式特定方法
US5830675A (en) * 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
ATE193601T1 (de) * 1993-03-10 2000-06-15 Cedars Sinai Medical Center Verfahren zum selektiven nachweis von perinuklearen anti-neutrophilen cytoplasmischen antikörpern bei ulzerativen kolitis oder primärer sclerotischer cholangitis
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US5874233A (en) * 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US5916748A (en) * 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US6074835A (en) * 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
WO1997038642A1 (en) * 1996-04-12 1997-10-23 Cedars-Sinai Medical Center Methods of determining the risk of pouchitis development
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
JP2001269196A (ja) * 2000-03-24 2001-10-02 Hamamatsu Photonics Kk 被検体核酸の定量方法、および被検体核酸の分子数の計数方法
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

Also Published As

Publication number Publication date
EP1556405B1 (de) 2010-03-31
AU2003263834A8 (en) 2004-03-19
ATE462710T1 (de) 2010-04-15
US20070072180A1 (en) 2007-03-29
JP4606877B2 (ja) 2011-01-05
WO2004020968A2 (en) 2004-03-11
EP1556405A4 (de) 2007-01-10
WO2004020968A3 (en) 2004-08-26
JP2011015686A (ja) 2011-01-27
US7790370B2 (en) 2010-09-07
AU2003263834A1 (en) 2004-03-19
JP2006500016A (ja) 2006-01-05
EP1556405A2 (de) 2005-07-27
US20040053263A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
DE60331941D1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
CA2282746A1 (en) Prediction of coronary artery disease
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
WO2003089897A3 (en) Diagnosis and treatment of vascular disease
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
Stone et al. Selection of acute stroke patients for treatment of visual neglect.
DE69231595D1 (de) Bestimmung von mutationen im zusammenhang mit dem digeorge-syndrom
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
Aaltonen et al. Motives for physical activity in older men and women: A twin study using accelerometer‐measured physical activity
WO2003020118A3 (en) Diagnosis and treatment of vascular disease
De Haes et al. Patient participation and decision control: are patient autonomy and well-being associated?
KR20220166952A (ko) 인공지능 기반의 치매 예측 시스템 및 이를 이용한 자가진단 방법
ATE449964T1 (de) DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
DE60033646D1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
AU2003233292A8 (en) Protein c polymorphisms
DE60229513D1 (de) Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten
WO2003104812A3 (en) DIAGNOSIS ASSAY FOR ALZHEIMER'S DISEASE BASED ON THE DETERMINATION OF THE HA DOLLAR G (B) 42 RATE: HA DOLLAR G (B) 40
EP1722225A4 (de) Verfahren zur diagnose der immunität wiederkehrenden spontanen schwangerschaftsabbruchs sowie verfahren zur behandlung und überwachung
GB0223655D0 (en) Method of diagnosis
NO20002176D0 (no) Diagnostikk og terapi av kronisk obstruktiv luftveissykdom
DE60329224D1 (de) Verfahren zur Bestimmung von zirkulierender DNS in Plasma und zum Nachweis von Krebs
WO2003007801A3 (en) Diagnosis and treatment of vascular disease
ATE413468T1 (de) Verfahren zur identifizierung abnormaler immunreaktionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition